finder.com

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Inozyme Pharma stock

Own Inozyme Pharma stock in just a few minutes.

Buy Inozyme Pharma (INZY)
Avatar
Jing Jun Ma
Fact checked

Inozyme Pharma, Inc is a biotechnology business based in the US. Inozyme Pharma shares (INZY) are listed on the NASDAQ and all prices are listed in US Dollars. Inozyme Pharma employs 38 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in Inozyme Pharma

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – INZY – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

What's in this guide?

  1. INZY shares summary
  2. Compare share dealing platforms
  3. Is INZY stock a buy or sell?
  4. Stock performance over time
  5. Can I short INZY shares?
  6. Inozyme Pharma's financials
  7. Does Inozyme Pharma pay a dividend?
  8. Other common questions

Inozyme Pharma share price

Use our graph to track the performance of INZY stocks over time.

Inozyme Pharma shares at a glance

Information last updated 2021-04-30.
52-week range$16.10 - $31.65
50-day moving average $19.58
200-day moving average $22.50
Wall St. target price$36.67
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-1.11

Buy Inozyme Pharma shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Go to site
More Info
Robinhood
Robinhood
$0
Stocks, Options, ETFs
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Go to site
More Info
Interactive Brokers
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Go to site
More Info
Webull
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Go to site
More Info
Public
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
Go to site
More Info
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Inozyme Pharma stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Inozyme Pharma, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Inozyme Pharma financials

Gross profit TTM $0
Return on assets TTM -32.81%
Return on equity TTM -55.64%
Profit margin 0%
Book value N/A
Market capitalisation $433.1 million

TTM: trailing 12 months

Shorting Inozyme Pharma shares

There are currently 1.4 million Inozyme Pharma shares held short by investors – that's known as Inozyme Pharma's "short interest". This figure is 8.3% up from 1.3 million last month.

There are a few different ways that this level of interest in shorting Inozyme Pharma shares can be evaluated.

Inozyme Pharma's "short interest ratio" (SIR)

Inozyme Pharma's "short interest ratio" (SIR) is the quantity of Inozyme Pharma shares currently shorted divided by the average quantity of Inozyme Pharma shares traded daily (recently around 56873.632038065). Inozyme Pharma's SIR currently stands at 25.22. In other words for every 100,000 Inozyme Pharma shares traded daily on the market, roughly 25220 shares are currently held short.

However Inozyme Pharma's short interest can also be evaluated against the total number of Inozyme Pharma shares, or, against the total number of tradable Inozyme Pharma shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Inozyme Pharma's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Inozyme Pharma shares in existence, roughly 60 shares are currently held short) or 0.0612% of the tradable shares (for every 100,000 tradable Inozyme Pharma shares, roughly 61 shares are currently held short).

A SIR above 20% would generally be considered very high, pointing to a pessimistic outlook for the share price, with a discouraging number of investors currently willing to bet against Inozyme Pharma.

Find out more about how you can short Inozyme Pharma stock.

Inozyme Pharma share dividends

We're not expecting Inozyme Pharma to pay a dividend over the next 12 months.

Inozyme Pharma overview

Inozyme Pharma, Inc. , a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as for the treatment of calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts. .

  1. Technical analysis graphic from TradingView, https://uk.tradingview.com Stock prices and other date from EOD Historical Data

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site